|
1.
|
|
12 p, 3.6 MB |
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
/
Jung, H. (Department of Bio and Brain Engineering. KAIST) ;
Kim, H.S. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Kim, J.Y. (Department of Bio and Brain Engineering. KAIST) ;
Sun, J.M. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Ahn, J.S. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Ahn, M.J. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Park, K. (Division of Hematology/Oncology. Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lee, S.H. (Department of Health Sciences and Technology. Samsung Advanced Institute of Health Science and Technology. Sungkyunkwan University) ;
Choi, J.K. (Penta Medix Co.. Ltd.) ;
Universitat Autònoma de Barcelona
Mitotic cell division increases tumour mutation burden and copy number load, predictive markers of the clinical benefit of immunotherapy. Cell division correlates also with genomic demethylation involving methylation loss in late-replicating partial methylation domains. [...]
2019 -  10.1038/s41467-019-12159-9
Nature communications, Vol. 10 Núm. 1 (january 2019) , p. 4278
|
|
|
2.
|
|
14 p, 2.0 MB |
Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation
/
Diesch, Jeannine (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bywater, M.J. (QIMR Berghofer Medical Research Institute) ;
Sanij, E. (Department of Pathology. University of Melbourne) ;
Cameron, D.P. (Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Schierding, W. (Liggins Institute. The University of Auckland) ;
Brajanovski, N. (Cancer Research Division. Peter MacCallum Cancer Centre) ;
Son, J. (Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Sornkom, J. (Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Hein, N. (ACRF Department of Cancer Biology and Therapeutics. John Curtin School of Medical Research. Australian National University) ;
Evers, M. (ACRF Department of Cancer Biology and Therapeutics. John Curtin School of Medical Research. Australian National University) ;
Pearson, R.B. (Department of Biochemistry and Molecular Biology. University of Melbourne) ;
McArthur, G.A. (Department of Medicine. St Vincent's Hospital. University of Melbourne) ;
Ganley, A.R.D. (School of Biological Sciences. The University of Auckland) ;
O'Sullivan, J.M. (Liggins Institute. The University of Auckland) ;
Hannan, R.D. (School of Biomedical Sciences. University of Queensland) ;
Poortinga, G. (Department of Medicine. St Vincent's Hospital. University of Melbourne) ;
Universitat Autònoma de Barcelona
The three-dimensional organization of the genome contributes to its maintenance and regulation. While chromosomal regions associate with nucleolar ribosomal RNA genes (rDNA), the biological significance of rDNA-genome interactions and whether they are dynamically regulated during disease remain unclear. [...]
2019 - 10.1038/s42003-019-0284-y
Communications Biology, Vol. 2 Núm. 1 (january 2019) , p. 39
|
|
|
3.
|
|
16 p, 2.3 MB |
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
/
Palomeras, S. (New Therapeutics Targets Lab (TargetsLab). Department of Medical Sciences. University of Girona) ;
Diaz-Lagares, Á. (Cancer Epigenomics. Translational Medical Oncology (Oncomet). Health Research Institute of Santiago (IDIS). University Clinical Hospital of Santiago(CHUS/SERGAS). CIBERONC) ;
Viñas, G. (Girona Biomedical Research Institute (IDIBGI)) ;
Setien, F. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). Hospitalet de Llobregat) ;
Ferreira, H.J. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). Hospitalet de Llobregat) ;
Oliveras, G. (Pathology Department. Dr. Josep Trueta Hospital and Catalan Institute of Health (ICS)) ;
Crujeiras, A.B. (CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn)) ;
Hernández, A. (Medical Oncology Department. Catalan Institute of Oncology (ICO)) ;
Lum, D.H. (Department of Oncological Sciences. Huntsman Cancer Institute. University of Utah) ;
Welm, A.L. (Department of Oncological Sciences. Huntsman Cancer Institute. University of Utah) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Puig, T. (New Therapeutics Targets Lab (TargetsLab). Department of Medical Sciences. University of Girona) ;
Universitat Autònoma de Barcelona
Background: Acquired resistance to trastuzumab is a major clinical problem in the treatment of HER2-positive (HER2+) breast cancer patients. The selection of trastuzumab-resistant patients is a great challenge of precision oncology. [...]
2019 - 10.1186/s13058-019-1160-x
Breast cancer research, Vol. 21 Núm. 1 (may 2019) , p. 79
|
|
|
4.
|
|
7 p, 979.5 KB |
Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer
/
Piqué, L. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Martinez de Paz, A. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Piñeyro, D. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Martínez Cardús, Anna (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Castro de Moura, M. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Llinàs-Arias, P. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Setien, F. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Gomez-Miragaya, J. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Gonzalez-Suarez, E. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Sigurdsson, S. (Department of Biochemistry and Molecular Biology. Biomedical Center) ;
Jonasson, J.G. (Department of Pathology. Landspitali University Hospital) ;
Villanueva, A. (Translational Research Laboratory. IDIBELL-Institut Catala d'Oncologia) ;
Vidal, A. (Department of Pathology. Bellvitge University Hospital) ;
Davalos, V. (Cancer Epigenetics and Biology Program (PEBC). Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Human tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. [...]
2019 - 10.1038/s41388-019-0936-x
Oncogene, Vol. 38 Núm. 45 (july 2019) , p. 7106-7112
|
|
|
5.
|
|
15 p, 2.9 MB |
MethCORR modelling of methylomes from formalin-fixed paraffin-embedded tissue enables characterization and prognostication of colorectal cancer
/
Mattesen, T.B. (Department of Molecular Medicine. Aarhus University Hospital) ;
Rasmussen, M.H. (Department of Molecular Medicine. Aarhus University Hospital) ;
Sandoval, J. (Biomarker and precision medicine Unit. Health Research Institute La Fe (ISSLaFe)) ;
Ongen, H. (Genetic Medicine and Development. University of Geneva Medical School-CMU) ;
Árnadóttir, S.S. (Department of Molecular Medicine. Aarhus University Hospital) ;
Gladov, J. (Department of Molecular Medicine. Aarhus University Hospital) ;
Martínez Cardús, Anna (Institut Germans Trias i Pujol) ;
Castro de Moura, Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Madsen, A.H. (Department of Surgery. Hospitalsenheden Vest) ;
Laurberg, S. (Colorectal Surgical Unit. Department of Surgery. Aarhus University Hospital) ;
Dermitzakis, E.T. (Genetic Medicine and Development. University of Geneva Medical School-CMU) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Andersen, C.L. (Department of Molecular Medicine. Aarhus University Hospital) ;
Bramsen, J.B. (Department of Molecular Medicine. Aarhus University Hospital) ;
Universitat Autònoma de Barcelona
Transcriptional characterization and classification has potential to resolve the inter-tumor heterogeneity of colorectal cancer and improve patient management. Yet, robust transcriptional profiling is difficult using formalin-fixed, paraffin-embedded (FFPE) samples, which complicates testing in clinical and archival material. [...]
2020 - 10.1038/s41467-020-16000-6
Nature communications, Vol. 11 Núm. 1 (january 2020) , p. 2025
|
|
|
6.
|
|
18 p, 4.0 MB |
Targeting OGG1 arrests cancer cell proliferation by inducing replication stress
/
Visnes, T. (Department of Biotechnology and Nanomedicine. Sintef Industry) ;
Benítez-Buelga, C. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Cázares-Körner, A. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Sanjiv, K. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Hanna, B.M.F. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Mortusewicz, O. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Rajagopal, V. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Albers, J.J. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Hagey, D.W. (Department of Laboratory Medicine. Karolinska Institutet) ;
Bekkhus, T. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Eshtad, S. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Baquero, J.M. (Human Genetics Group. Spanish National Cancer Research Centre (CNIO)) ;
Masuyer, G. (Department of Pharmacy and Pharmacology. Centre for Therapeutic Innovation. University of Bath) ;
Wallner, O. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Müller, S. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Pham, T. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Göktürk, C. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Rasti, A. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Suman, S. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sarno, A. (Department of Environment and New Resources. Sintef Ocean) ;
Wiita, E. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Homan, E.J. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Karsten, S. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Marimuthu, K. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Michel, M. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Koolmeister, T. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Scobie, M. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Loseva, O. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Almlöf, I. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Unterlass, J.E. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Pettke, A. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Boström, J. (Science for Life Laboratory. Division of Clinical Physiology. Department of Laboratory Medicine. Karolinska Institutet) ;
Pandey, M. (Weston Park Cancer Centre. Department of Oncology and Metabolism. University of Sheffield) ;
Gad, H. (Weston Park Cancer Centre. Department of Oncology and Metabolism. University of Sheffield) ;
Herr, P. (Weston Park Cancer Centre. Department of Oncology and Metabolism. University of Sheffield) ;
Jemth, A.S. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
El Andaloussi, S. (Department of Laboratory Medicine. Karolinska Institutet) ;
Kalderén, C. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Rodriguez-Perales, S. (Molecular Cytogenetics Group. Human Cancer Genetics Program. Spanish National Cancer Research Centre (CNIO)) ;
Benítez, J. (Spanish Network on Rare Diseases (CIBERER)) ;
Krokan, H.E. (The Liaison Committee for Education. Research and Innovation in Central Norway) ;
Altun, M. (Science for Life Laboratory. Division of Clinical Physiology. Department of Laboratory Medicine. Karolinska Institutet) ;
Stenmark, P. (Department of Experimental Medical Science. Lund University) ;
Berglund, U.W. (Science for Life Laboratory. Department of Oncology and Pathology. Karolinska Institutet) ;
Helleday, T. (Weston Park Cancer Centre. Department of Oncology and Metabolism. University of Sheffield) ;
Universitat Autònoma de Barcelona
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e. g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. [...]
2021 - 10.1093/nar/gkaa1048
Nucleic acids research, Vol. 48 Núm. 21 (february 2021) , p. 12234-12251
|
|
|
7.
|
|
13 p, 2.2 MB |
Epigenetic regulation of gfi1 in endocrine-related cancers : A role regulating tumor growth
/
Ashour, N. (Departamento de Biología de Sistemas. Unidad Docente de Bioquímica y Biología Molecular. Universidad de Alcalá) ;
Angulo, J.C. (Servicio de Urología. Hospital Universitario de Getafe. Fundación para la Investigación Biomédica del Hospital Universitario de Getafe. Universidad Europea de Madrid) ;
González-Corpas, A. (Departamento de Biología de Sistemas. Unidad Docente de Bioquímica y Biología Molecular. Universidad de Alcalá) ;
Orea, M.J. (Departamento de Biología de Sistemas. Unidad Docente de Bioquímica y Biología Molecular. Universidad de Alcalá) ;
Lobo, M.V.T. (Departamento de Biomedicina y Biotecnología. Universidad de Alcalá. Instituto Ramón y Cajal de Investigaciones Sanitarias (IRYCIS)) ;
Colomer, R. (Department of Medicine. Universidad Autónoma de Madrid) ;
Colás, B. (Departamento de Biología de Sistemas. Unidad Docente de Bioquímica y Biología Molecular. Universidad de Alcalá) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ropero, S. (Departamento de Biología de Sistemas. Unidad Docente de Bioquímica y Biología Molecular. Universidad de Alcalá) ;
Universitat Autònoma de Barcelona
Prostate and breast cancer constitute the most common cancers among men and women worldwide. The aging population is one of the main risk factors for prostate and breast cancer development and accumulating studies link aging with epigenetic changes. [...]
2020 - 10.3390/ijms21134687
International journal of molecular sciences, Vol. 21 Núm. 13 (july 2020) , p. 1-12
|
|
|
8.
|
|
19 p, 3.1 MB |
Molecular context-dependent effects induced by rett syndrome-associated mutations in mecp2
/
Ortega-Alarcon, D. (Institute of Biocomputation and Physics of Complex Systems (BIFI). Joint Units IQFR-CSIC-BIFI,and GBsC-CSIC-BIFI. Universidad de Zaragoza) ;
Claveria-Gimeno, R. (Instituto de Investigación Sanitaria Aragón (IIS Aragón)) ;
Vega, S. (Institute of Biocomputation and Physics of Complex Systems (BIFI). Joint Units IQFR-CSIC-BIFI,and GBsC-CSIC-BIFI. Universidad de Zaragoza) ;
Jorge-Torres, Olga C. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Abian, O. (Departamento de Bioquímica y Biología Molecular y Celular. Universidad de Zaragoza) ;
Velazquez-Campoy, A. (Fundación ARAID. Gobierno de Aragón) ;
Universitat Autònoma de Barcelona
Methyl-CpG binding protein 2 (MeCP2) is a transcriptional regulator and a chromatinbinding protein involved in neuronal development and maturation. Loss-of-function mutations in MeCP2 result in Rett syndrome (RTT), a neurodevelopmental disorder that is the main cause of mental retardation in females. [...]
2020 - 10.3390/biom10111533
Biomolecules, Vol. 10 Núm. 11 (november 2020) , p. 1-18
|
|
|
9.
|
|
14 p, 892.1 KB |
Discovery of novel DNA methylation biomarkers for non-invasive sporadic breast cancer detection in the Latino population
/
Cappetta, M. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Fernandez, L. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Brignoni, L. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Artagaveytia, N. (Departamento Básico de Medicina. Facultad de Medicina. Universidad de la República) ;
Bonilla, C. (Population Health Sciences. Bristol Medical School. University of Bristol) ;
López, Miguel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bertoni, B. (Departamento de Genética. Facultad de Medicina. Universidad de la República) ;
Berdasco, Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Human diversity is one of the main pitfalls in the development of robust worldwide biomarkers in oncology. Epigenetic variability across human populations is associated with different genetic backgrounds, as well as variable lifestyles and environmental exposures, each of which should be investigated. [...]
2021 - 10.1002/1878-0261.12842
Molecular Oncology, Vol. 15 Núm. 2 (february 2021) , p. 473-486
|
|
|
10.
|
|
16 p, 1.9 MB |
Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
/
Ji, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Lin, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shen, S. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Dong, X. (Department of Epidemiology and Biostatistics. School of Public Health. Southeast University) ;
Chen, C. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Li, Y. (Department of Biostatistics. University of Michigan) ;
Zhu, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Huang, H. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Wei, L. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
He, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Duan, W. (Department of Bioinformatics. School of Biomedical Engineering and Informatics. Nanjing Medical University) ;
Su, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Jiang, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Fan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Guan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
You, D. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shafer, A. (Pulmonary and Critical Care Division. Department of Medicine. Massachusetts General Hospital and Harvard Medical School) ;
Bjaanæs, M.M. (Department of Cancer Genetics. Institute for Cancer Research. Oslo University Hospital) ;
Karlsson, A. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Planck, M. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Staaf, J. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Helland, Å. (Institute of Clinical Medicine. University of Oslo) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Wei, Y. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Zhang, R. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Chen, F. (Jiangsu Key Lab of Cancer Biomarkers. Prevention and Treatment. Cancer Center. Collaborative Innovation Center for Cancer Personalized Medicine. Nanjing Medical University) ;
Christiani, D.C. (Pulmonary and Critical Care Division. Department of Medicine. Massachusetts General Hospital and Harvard Medical School) ;
Universitat Autònoma de Barcelona
Tripartite motif containing 27 (TRIM27) is highly expressed in lung cancer, including non-small-cell lung cancer (NSCLC). Here, we profiled DNA methylation of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tumours from 613 early-stage NSCLC patients and evaluated associations between CpG methylation of TRIM27 and overall survival. [...]
2020 - 10.1002/1878-0261.12785
Molecular Oncology, Vol. 14 Núm. 11 (january 2020) , p. 2759-2774
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
